Your AI-Trained Oncology Knowledge Connection!
Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.
Badrinath Konety, MD, MBA, department chair, Department of Urology, University of Minnesota, discusses the guidelines for the management of patients with bladder cancer.
Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.
Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.
As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.
Direct acting antivirals are a novel and completely oral hepatitis C therapy that is associated with a high response rate in hepatocellular carcinoma (HCC).
BLU-554 induced an overall response rate of 16% in patients with FGF19-positive hepatocellular carcinoma.
Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses endocrine therapy for patients with breast cancer.
Arti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, City of Hope, discusses challenges facing geriatric patients with breast cancer.
Ongoing studies are hoping to find a biomarker to guide which premenopausal women with ER-positive breast cancer need extended adjuvant therapy and which need ovarian function suppression.
Treating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.
The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.
Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the purpose of the CheckMate-040 trial, which explored nivolumab (Opdivo) in patients with hepatocellular carcinoma. (HCC).
Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses biomarker findings of the phase III STORM trial, which explored adjuvant treatment with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).
First-line therapy with lenvatinib continued to be noninferior in overall survival and achieve significant improvements in progression-free survival, time to progression, and objective response rate compared with sorafenib for patients with unresectable hepatocellular carcinoma.
Health investment is failing to match the challenge presented by a growing cancer burden in countries at all economic levels, enhancing the need for new approaches that help optimize the delivery of care.
There is a significant transformation underway in the treatment of breast cancer as research advances and new laboratory techniques continue to shrink the so-called "undruggable genome."
Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses adjuvant therapy for elderly patients with HER2-positive or triple-negative breast cancer (TNBC).
Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival for patients with hepatocellular carcinoma treated with adjuvant sorafenib; however, a predictive biomarker for recurrence was not uncovered.
Precision screening for hepatocellular carcinoma (HCC) could improve on current screening techniques through its risk-stratifying approach.
Patients have a hard time with artificially induced menopause and some research suggests it may have a negligible effect on the success of their treatment.
Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses treatment for premenopausal patients with breast cancer.
Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).
Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agents will eventually fit into the paradigm of hepatocellular carcinoma. (HCC).
Theodore H. Welling, MD, shares insight on the top presentations at the ILCA meeting, and how he believes the future will look for the treatment of HCC.
José Baselga, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses biomarker research for patients with breast cancer.
Benjamin O. Anderson, MD, a surgical oncologist at the Seattle Cancer Care Alliance, discusses the biggest unmet need for patients with breast cancer in low- and middle-income countries.
Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses advancements regarding systemic therapies in the field of hepatocellular carcinoma (HCC).
Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).
The 11th International Liver Cancer Association Annual Conference, taking place September 15 to 17 in Seoul, South Korea, is showcasing multidisciplinary findings across the field of hepatocellular carcinoma.
